According to data collected from various sources and compiled by Coherent Market Insights, Europe have the highest annual rate of incidence worldwide, followed by North America and the lowest in Asia and Middle East.

However, North America holds the largest share in the global Ulcerative Colitis Market due to continuous improvements in drugs, increased uptake of medicines, awareness about treatment and increasing clinical research. APAC region will show high growth in ulcerative colitis market during forecast years (2017-2024), due to raising awareness about the treatment, changing lifestyle will cause to increase prevalence and incidence rate, entry of new drugs in the market also some companies losing their patent of ulcerative drugs in coming years, like Humira (adalimumab) lost its patent in 2016 and Remicade will lose its patent in 2018. Also, some drugs companies have launched their biosimilar drugs in ulcerative colitis industry. For example, in 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.

Some major companies playing leading role in ulcerative colitis market are AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.

Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan and blood test.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/238

If ulcerative colitis persists for over 8 years or longer, it may lead to colon cancer. The people having mild symptoms of this disease can be cured by over the counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps prevent colon cancer.

Also, some genetically engineered drugs also used to treat ulcerative colitis. These drugs are made up of certain living organisms that help suppress the inflammation, by targeting the inflammatory proteins such as cytokines. Some genetically engineered drugs approved by the U.S. FDA for treatment of the condition are Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio).

These genetically engineered drugs may show some side effects such as fever, headache, hives, low blood pressure, breathing difficulties, back pain, and stomach pain. Also, these drugs may affect the immunity power of body to fight infection.

The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well hydrated throughout the day, avoiding fatty foods, and limiting intake of high-fiber food.

According to data released by the Centers for Disease Control and Prevention (CDC), there are around 2.2 to 14.3 cases found per 100,000 population per year. Also, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from ulcerative colitis in the U.S. (data based on the research conducted in between 2011-2014 by CCFA)

High prevalence in developed regions and increasing incidence rate in emerging economies will play major role in driving growth of the ulcerative colitis market

According to the study of CCFA, industrialized countries have highest incidence rate for ulcerative colitis. This disease is most prevalent in urban areas than in rural areas, also it can affect to any age group of people but most cases diagnosed are of the age in between 15 to 35. According the stats of World Gastroenterology Organization (WGO), there is rising incidence rate in emerging economies such as India. Due to changing diet and lifestyle pattern, the emerging economies will show high growth rate in incidence rate of ulcerative colitis in the near future.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/ulcerative-colitis-market-238

Some leading drugs are used to reduce inflammation and swelling and to cure ulcerative colitis are include Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), and Infliximab (Remicade).

Key Developments

Key players in the market are focused on various growth strategies such research and development of novel products, in order to enhance their product portfolio. For instance, in October 2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness and safety in the treatment of ulcerative colitis in a 24-month open label extension study.

Major companies in the market are involved in various business strategies such research and development of novel products, in order to enhance their product portfolio. For instance, in March 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Phase III data UNFI study data for Stelara, a subcutaneous maintenance therapy, which showed positive results as maintenance therapy in adults suffering from moderate to severe ulcerative colitis.

Major companies in the market are involved in various growth strategies such research and development of novel products, in order to enhance their market presence. For instance, in August 2019, Takeda Pharmaceutical Company Limited, submitted new drug application (NDA) to Ministry of Health, Labour and Welfare in Japan for subcutaneous formulation of vedolizumab, which will be used as maintenance therapy in adults with moderate to severe ulcerative colitis.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/238

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737